Hemostemix Inc.
HEM
Ранг среди акций
#32552
Hemostemix Inc., a clinical stage biotechnology company, develops,... Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which is in Phase II clinical trial for the treatment of vascular diseases, such as peripheral arterial disease, angina pectoris, and ischemia, as well as heart failure, ischemic and dilated cardiomyopathy, chronic limb threatening ischemia, vascular dementia, and brain function. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.
Цена акции
$0.04268108
Последняя синхронизация: 2026-10-21
Рыночная капитализация
$9.02M
Изменение (1 день)
5.73%
Изменение (1 год)
-42.09%
Страна
CA
Торговля Hemostemix Inc. (HEM)
Категория
Healthcare
История цены акций Hemostemix Inc. (HEM)
Наивысшая цена закрытия: $0.04 2026-10-01
Наименьшая цена закрытия: $0.00 2005-11-01
Наименьшая цена закрытия: $0.00 2005-11-01
История цены акций Hemostemix Inc. с 2005 по 2026
Годовая динамика цены акций
| Год | Результативность |
|---|---|
| 2026 (TTM) | -11.95% |
| 2025 | 20.30% |
| 2024 | -2.01% |
| 2023 | -53.19% |
| 2022 | -8.06% |
| 2021 | 925.13% |
| 2020 | 7.84% |
| 2019 | -99.16% |
| 2018 | 984,477.83% |
| 2017 | 242.51% |
| 2016 | -91.14% |
| 2015 | 0.00% |
| 2014 | 0.00% |
| 2013 | 0.00% |
| 2012 | 0.00% |
| 2011 | 0.00% |
| 2010 | -1.41% |
| 2009 | -34.26% |
| 2008 | -72.09% |
| 2007 | 17.99% |
| 2006 | 72.63% |
| 2005 | 0.00% |
Цена акций похожих компаний или конкурентов
| Компания | Цена акций | Изменение 1г% | Страна |
|---|---|---|---|
| $535.96 | 25.68% |
US
|
|
| $186.23 | 593.59% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $892.29 | 9.59% |
NL
|
